RxDoctor Payments Data

Daisy Behman, MD

Endocrinology, Diabetes & Metabolism · Carteret, NJNPI 1780694166

Payments from drug & device makers

$6,840in general payments, 2019–2025

Across 369 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$961
  • Lilly USA, LLC$880
  • Corcept Therapeutics$608
  • AstraZeneca$497
  • Abbott$395
  • Dexcom, Inc.$363
  • plus $3K from 48 others

What the payments were for

  • Food & beverage$6,817100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,840 in reported general payments places this provider in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey

Medicare billing

Part B allowed, 2024
$160,756
Medicare patients
246
Services billed
1,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide199$340,155
MounjaroTirzepatide72$109,551
FarxigaDapagliflozin Propanediol77$83,286
JardianceEmpagliflozin74$81,722
RybelsusSemaglutide45$80,071
TrulicityDulaglutide42$64,729
Tresiba Flextouch U-200Insulin Degludec28$39,967
JanuviaSitagliptin Phosphate25$28,771
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$28,657
Fiasp FlextouchInsulin Aspart (Niacinamide)25$28,044
Tresiba Flextouch U-100Insulin Degludec42$26,332
Humalog Kwikpen U-200Insulin Lispro28$25,534
Bydureon BciseExenatide Microspheres19$25,170
Synjardy XrEmpagliflozin/Metformin Hcl19$22,743
Novolog FlexpenInsulin Aspart51$15,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$961$425,800255 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$880$176,981128 claims
Boehringer IngelheimJardiance, Synjardy Xr$148$104,46493 claims
AstraZenecaFarxiga$497$83,28677 claims
MerckJanuvia$103$28,77125 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$78$2,895259 claims
AbbVieSynthroid$282$1,83821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

Other endocrinology, diabetes & metabolism in Carteret

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →